New technique generates rod photoreceptors that integrate into the retina and brain.
Researchers funded by the National Eye Institute (NEI) have reversed congenital blindness in mice by changing supportive cells in the retina called Müller glia into rod photoreceptors. The findings advance efforts toward regenerative therapies for blinding diseases such as age-related macular degeneration and retinitis pigmentosa. A report of the findings appears online today in Nature. NEI is part of the National Institutes of Health.
“This is the first report of scientists reprogramming Müller glia to become functional rod photoreceptors in the mammalian retina,” said Thomas N. Greenwell, Ph.D., NEI program director for retinal neuroscience. “Rods allow us to see in low light, but they may also help preserve cone photoreceptors, which are important for color vision and high visual acuity. Cones tend to die in later-stage eye diseases. If rods can be regenerated from inside the eye, this might be a strategy for treating diseases of the eye that affect photoreceptors.”
Photoreceptors are light-sensitive cells in the retina in the back of the eye that signal the brain when activated. In mammals, including mice and humans, photoreceptors fail to regenerate on their own. Like most neurons, once mature they don’t divide.
Scientists have long studied the regenerative potential of Müller glia because in other species, such as zebrafish, they divide in response to injury and can turn into photoreceptors and other retinal neurons. The zebrafish can thus regain vision after severe retinal injury. In the lab, however, scientists can coax mammalian Müller glia to behave more like they do in the fish. But it requires injuring the tissue.
“From a practical standpoint, if you’re trying to regenerate the retina to restore a person’s vision, it is counterproductive to injure it first to activate the Müller glia,” said Bo Chen, Ph.D., associate professor of ophthalmology and director of the Ocular Stem Cell Program at the Icahn School of Medicine at Mount Sinai, New York.
“We wanted to see if we could program Müller glia to become rod photoreceptors in a living mouse without having to injure its retina,” said Chen, the study’s lead investigator.
In the first phase of a two-stage reprogramming process Chen’s team spurred Müller glia in normal mice to divide by injecting their eyes with a gene to turn on a protein called beta-catenin. Weeks later, they injected the mice’s eyes with factors that encouraged the newly divided cells to develop into rod photoreceptors.
The researchers used microscopy to visually track the newly formed cells. They found that the newly formed rod photoreceptors looked structurally no different from real photoreceptors. In addition, synaptic structures that allow the rods to communicate with other types of neurons within the retina had also formed. To determine whether the Müller glia-derived rod photoreceptors were functional, they tested the treatment in mice with congenital blindness, which meant that they were born without functional rod photoreceptors.
In the treated mice that were born blind, Müller glia-derived rods developed just as effectively as they had in normal mice. Functionally, they confirmed that the newly formed rods were communicating with other types of retinal neurons across synapses. Furthermore, light responses recorded from retinal ganglion cells — neurons that carry signals from photoreceptors to the brain — and measurements of brain activity confirmed that the newly-formed rods were in fact integrating in the visual pathway circuitry, from the retina to the primary visual cortex in the brain.
Chen’s lab is conducting behavioral studies to determine whether the mice have regained the ability to perform visual tasks such as a water maze task. Chen also plans to see if the technique works on cultured human retinal tissue.
The Latest on: Congenital blindness
via Google News
The Latest on: Congenital blindness
- Gene Therapies: What to Knowon November 25, 2020 at 10:07 am
David Israel was diagnosed with lymphoma in 2015, the start of a two-year gauntlet of treatments including chemotherapy and a stem cell transplant. The cancer kept winning, and in the summer of ...
- Finding a Fix for Faulty Geneson November 25, 2020 at 7:57 am
In August 2017, Israel’s T cells were collected from his blood and their genes were altered to recognize and target CD19, a protein on the surface of lymphoma cells. The engineered T cells were ...
- ProQR Announces Third Quarter 2020 Operating and Financial Resultson November 16, 2020 at 4:02 am
(GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases ...
- Liminal BioSciences Inc. LMNLon November 12, 2020 at 8:35 am
The company is preparing to resubmit a BLA (( DONE )) to use the congenital replacement therapy as a treatment ... usually around the eyes, which can cause blindness, as well as other regions ...
- More Babies In The U.S. Are Dying Because Of Congenital Syphilison November 12, 2020 at 5:34 am
"Or they might have severe illness like blindness or deafness or other types ... The rising rates in congenital syphilis might betray a larger problem among health care for women and pregnant ...
- Masimo Founder and CEO and Co-Inventor of Measure-Through-Motion Pulse Oximetry, Joe Kiani, Awarded by the Ibero-American Society of Neonatology for Improvements to Neonatal ...on November 9, 2020 at 4:00 am
Joe Kiani, Founder & CEO of Masimo & co-inventor of measure-through-motion pulse oximetry, was honored by SIBEN for improvements to neonatal health.
- Deuteranopia: How to Tell If You Have Red-Green Color Blindnesson November 8, 2020 at 4:00 pm
Red-green color blindness is the most common type of color deficiency. Also known as deuteranopia, this is most likely a congenital condition, meaning that you’re born with it. If you have this ...
- Down Syndrome Gene Suppresses Corneal Cloudingon November 8, 2020 at 10:14 am
In patients with high cholesterol, a Down syndrome-associated gene, DSCR-1 was found to protect against abnormal vascularization of the cornea and associated corneal opacity (blindness ...
- Down Syndrome-associated gene suppresses age-related corneal cloudingon November 6, 2020 at 11:31 am
Down syndrome and hypercholesterolemia mouse models suggest that the DSCR-1 gene protects against abnormal cornea vascularization and associated blindness ... the most common congenital disease ...
via Bing News